Servier Bets $2.65B on Edgewise’s Muscular Dystrophy Business

Daily Biopharma Digest — June 1, 2026

• Servier’s $2.65 billion acquisition of Edgewise’s muscular dystrophy business headlines a busy day of late-stage dealmaking and ASCO-driven catalysts.
• Vertex gains FDA acceptance for its IgA nephropathy BLA under the accelerated approval pathway.
• AstraZeneca secures approval for Imfinzi plus BCG in bladder cancer.
• Clinical data from ASCO continues to reshape treatment landscapes, particularly Revolution Medicines’ pancreatic cancer breakthrough.

What to Watch

• Vertex’s November PDUFA Date — The accelerated approval pathway for povetacicept in IgA nephropathy sets up a critical fourth-quarter readout that could establish Vertex in rare kidney disease, but confirmatory trial execution will determine long-term commercial viability.
• Servier’s Sevasemten Pivotal Data — With $1.55 billion committed upfront, all eyes turn to the muscular dystrophy program’s upcoming pivotal readout this year, which will validate or challenge the deal’s blockbuster thesis and Servier’s neurology ambitions.
• Obesity Pipeline Consolidation — Lilly’s $1.26 billion Hanmi deal and continued ASCO data in metabolic-adjacent indications suggest the cardiometabolic space remains hot despite crowding, with both big pharma and biotechs racing to secure next-generation assets.
• Rare Disease Bispecific Expansion — Regeneron’s 90% complete response rate in light chain amyloidosis points to broader potential for bispecific antibodies beyond their initial indications, potentially opening multiple niche markets with limited competition.